For the management of people with hypertension, Telmisartan is promising and efficacious as single and double-dose monotherapy, combined with Hydrochlorothiazide or Amlodipine, and therapy for hypertension with dyslipidemia or diabetes people, as deciphered from a recent systematic review.

This study was created to analyze the most recent information regarding Telmisartan's effectiveness in patients with hypertension. The effectiveness of Telmisartan as a double or single-dose monotherapy, along with Hydrochlorothiazide or Amlodipine, or as a therapeutic option for hypertension along with diabetes or for dyslipidemia people with blood pressure and triglycerides or low-density lipoproteins cholesterol or post-meal blood sugar or fasting insulin or fasting plasma glucose was searched for in PubMed, ScienceDirect, and Hindawi.

The PRISMA flowchart was then applied to the articles that met the restriction requirements. Using GRADE technique, the articles' quality was assessed. The article searches revealed 1033 journals. Notably, 12 of them included publications that qualified for systematic reviews and scored highly on the GRADE scale, 1 had a moderate score, and 1 had a low score. Single-dose Telmisartan monotherapy considerably minimized blood pressure (±5.61/5.15 mmHg) in comparison with double-dose therapy (21.8 ± 5.592/16.00 ±5.965 mmHg).

Following eight weeks, the combination of Telmisartan and Amlodipine remarkably lowered blood pressure (−15.3 ± 11.2/−8.0 ± 8.6 mmHg), and when combined with hydrochlorothiazide, the reduction was −31.1−18.1 mmHg. Telmisartan substantially decreased blood pressure (−24.9/−19.5 mmHg), post-meal blood sugar (−36.9 mg/dL) following 12 weeks, along with fasting plasma glucose (−1.06 mg/dL) and fasting insulin (−0.818 µU/mL) in patients with diabetes and hypertension. For treatment with anti-cholesterol agents, Telmisartan exhibits good tolerability.